Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence.

doi:10.1155/2020/5845374

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence.

BioMed research international - 1 Jan 2020

Kind Simon, Kluth Martina, Hube-Magg Claudia, Möller Katharina, Makrypidi-Fraune Georgia, Lutz Florian, Lennartz Maximilian, Rico Sebastian Dwertmann, Schlomm Thorsten, Heinzer Hans, Höflmayer Doris, Weidemann Sören, Uhlig Ria, Huland Hartwig, Graefen Markus, Bernreuther Christian, Tsourlakis Maria Christina, Minner Sarah, Dum David, Hinsch Andrea, Lübke Andreas M, Simon Ronald, Sauter Guido, Marx Andreas, Polonski Adam

Abstract excerpt

Syndecan-1 (CD138) is a transmembrane proteoglycan expressed in various normal and malignant tissues. It is of interest due to a possible prognostic effect in tumors and its role as a target for the antibody-drug conjugate indatuximab ravtansine. Here, we analyzed 17,747 prostate cancers by immunohistochemistry. Membranous and cytoplasmic CD138 staining was separately recorded. In normal prostate glands, CD138...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multivariate Analysis

Share to Neoplasm Invasiveness

Share to Neoplasm Recurrence, Local

Share to Oncogene Proteins, Fusion

Share to Proportional Hazards Models

Share to Prostate

Share to Syndecan-1

Source

Open in PubMed Open full text

Identifiers

PMID: 33195694
DOI: 10.1155/2020/5845374
PMCID: PMC7641694

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence.PMID 33195694Read ↗

Syndecan-1 (CD138), Carcinomas and EMTSemantic proximity Read ↗

Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia.Semantic proximity Read ↗

Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.Semantic proximity Read ↗

Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.Semantic proximity Read ↗

Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer.Semantic proximity Read ↗

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.Semantic proximity Read ↗

Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.